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Abstract
Background: There is an ongoing search for biomarkers in psychiatry, for example, as diagnostic tools or predictors of 
treatment response. The neurotrophic factor S100 calcium binding protein B (S100B) has been discussed as a possible predictor 
of antidepressant response in patients with major depression, but also as a possible biomarker of an acute depressive state. 
The aim of the present study was to study the association of serum S100B levels with antidepressant treatment response and 
depression severity in melancholically depressed inpatients.
Methods: After a wash-out period of 1 week, 40 inpatients with melancholic depression were treated with either venlafaxine 
or imipramine. S100B levels and Hamilton Depression Rating Scale (HAM-D) scores were assessed at baseline, after 7 weeks 
of treatment, and after 6 months.
Results: Patients with high S100B levels at baseline showed a markedly better treatment response defined as relative 
reduction in HAM-D scores than those with low baseline S100B levels after 7 weeks (P  =  .002) and 6 months (P = .003). In linear 
regression models, S100B was a significant predictor for treatment response at both time points. It is of interest to note 
that nonresponders were detected with a predictive value of 85% and a false negative rate of 7.5%. S100B levels were not 
associated with depression severity and did not change with clinical improvement.
Conclusions: Low S100B levels predict nonresponse to venlafaxine and imipramine with high precision. Future studies 
have to show which treatments are effective in patients with low levels of S100B so that this biomarker will help to 
reduce patients’ burden of nonresponding to frequently used antidepressants.
Keywords: Major depression, predictive biomarker, antidepressant response, treatment resistance, neurotrophic factor
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Introduction
Biomarkers are objective measures of biological processes and 
can be used as either a diagnostic tool to identify patients with 
a particular psychiatric disorder or as predictors of a patient’s 
response to treatment (Biomarkers Definitions Working Group, 
2001). Such biomarkers, for instance, can be alterations in blood 
levels of single molecules, genetic variants, epigenetic changes, 
or neuroimaging findings, among others (Kennedy et al., 2012; 
Boksa, 2013). In psychiatry, there is an unmet need for biomark-
ers in order to reduce patients’ suffering and costs of treatment 
by improving diagnostics and predicting treatment response. 
In addition, funding agencies and pharmaceutical companies 
increasingly request objective measures besides clinical data to 
invest in psychiatric research in the future (Kapur et al., 2012).
One potential biomarker that seems to be involved in sev-
eral psychiatric disorders is the S100 calcium binding protein 
B (S100B) (Schroeter et al., 2013; Yelmo-Cruz et al., 2013). In the 
brain, this protein is mainly expressed in astrocytes and to a 
certain extent also in oligodendrocytes (Steiner et  al., 2007; 
Gos et  al., 2013). It has several intra- and extracellular func-
tions, including regulation of cell proliferation, differentiation 
and survival, and Ca2+ homeostasis (Rothermundt et  al., 2003; 
Donato et  al., 2009). In particular, it has been shown to exert 
neurotrophic functions in a dose-dependent manner stimulat-
ing neurite outgrowth, enhancing survival of neurons and sup-
porting the development of serotonergic neurons (Alexanian 
and Bamburg, 1999; Huttunen et  al., 2000; Eriksen and Druse, 
2001).
In psychiatric disorders, S100B was investigated by assessing 
serum levels, levels in cerebrospinal fluid (CSF) and variants in 
the S100B gene. Genetic variants were found to be associated 
with the psychotic subtype of bipolar disorder, visuospatial dis-
ability in schizophrenia, and recurrence of major depression 
(Roche et al., 2007; Yang et al., 2009; Zhai et al., 2011). CSF levels 
were elevated in patients with major depression and schizo-
phrenia compared with controls (Grabe et al., 2001; Rothermundt 
et  al., 2004; Steiner et  al., 2006). S100B levels were also found 
to be higher in serum samples of patients with schizophrenia, 
major depression, and bipolar disorder (Schroeter et  al., 2013; 
Yelmo-Cruz et  al., 2013). Nonetheless, there are some incon-
clusive reports whether S100B levels in major depression are 
always elevated (Jang et al., 2008) and if these levels decline with 
successful treatment (eg, Schroeter et al., 2008).
Other studies reported that elevated S100B levels in depres-
sive patients at the beginning of an antidepressant treatment 
correlate with subsequent treatment response (Arolt et al., 2003; 
Jang et  al., 2008), suggesting that elevated S100B levels might 
contribute to a successful treatment. Patients in these studies 
were treated naturalistically in a standard hospital setting. One 
study reported an association between elevated S100B levels 
and illness severity (Jang et al., 2008), leaving open whether the 
correlation of treatment response and S100B levels was only 
a statistical effect, because the more depressive patients with 
higher S100B levels had a larger range to improve.
Therefore, the aim of this study was to analyze the predic-
tive value of serum S100B levels for antidepressant treatment 
response in a randomly assigned, double-blind treatment trial 
with either the serotonine-norepinephrine reuptake inhibitor 
venlafaxine or the tricyclic antidepressant imipramine. Based 
on the previous findings, it was hypothesized that patients with 
high S100B levels at baseline would respond better to antide-
pressant treatment. Since some studies also reported an asso-
ciation of S100B levels with depression severity, S100B levels 
were controlled for this association and monitored at baseline 
and after treatment in order to elucidate whether S100B levels in 
melancholic depression represent a trait marker for antidepres-
sant responsiveness or a state marker for the current severity 
of the disorder.
Methods
Study Design
The analysis of S100B as biomarker for antidepressant response 
was designed as an add-on study to a clinical trial on the efficacy 
and tolerability of the tricyclic antidepressant imipramine and 
the serotonin-norepinephrine reuptake inhibitor venlafaxine 
(Vermeiden et al., 2013). These drugs were selected because they 
appeared to be more effective than selective serotonin reup-
take inhibitors in inpatients with severe major depression. After 
a drug-free wash-out period of 7 days, patients were assigned 
to antidepressant treatment with either venlafaxine or imipra-
mine in a randomized double-blind trial. The treatment phase 
lasted 7 weeks, during which depression severity was moni-
tored weekly by the 17-item version of the Hamilton Depression 
Rating Scale (HAM-D). Blood sampling took place after the wash-
out phase before treatment started (baseline), after the 7-week 
treatment period (+7wks), and at the 6-month follow-up inves-
tigation (+6mos). The first time point was elected to assure that 
patients receive the maximum dose of venlafaxine and the opti-
mal dose with therapeutic plasma levels of imipramine for at 
least 4 weeks. The time point of 6 months was chosen to assess 
whether patients attaining response would show sustaining 
response after continuation treatment for another 4  months. 
The study was approved by the Medical Ethics Committee of the 
Erasmus Medical Center Rotterdam. The protocol was carried 
out in accordance with the ethical standards laid down in the 
Declaration of Helsinki (1964), as amended in Edinburgh (2000). 
All patients gave written informed consent after study proce-
dures had been explained in detail.
Patients
Patients suffering from major depression were consecutively 
recruited at the inpatient depression unit of the Department 
of Psychiatry of the Erasmus Medical Center Rotterdam. All 
depressed patients admitted to the depression unit meeting 
inclusion criteria and willing to participate enrolled in the origi-
nal study, which comprised 85 patients diagnosed with major 
depression including melancholic features according to DSM-
IV-TR (SCID-1) and a minimum HAM-D score of 17 (Vermeiden 
et al., 2013). Of those, 55 patients gave informed consent for 
the biomarker study. Another 15 patients were not included: 3 
patients refused participation after randomization, 10 patients 
had major depression with psychotic features, and 2 patients 
lacked melancholic features. Thus, the present study comprised 
40 consecutive patients with melancholic and without psychotic 
features. To be included in the study, patients were not allowed 
to meet one or more of the following criteria: incapable of under-
standing the information and to give informed consent; unable 
to read or write; bipolar I or II disorder; presence of psychotic 
features, schizophrenia, or other primary psychotic disorder; 
drug/alcohol dependence for the last 3 months; any clinically 
relevant renal, hepatic, endocrine, or neurologic illness; and 
use of steroids or nonsteroidal antiinflammatory drugs. Women 
were not included if they were pregnant or breastfeeding.
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Medication
After a drug-free wash-out period of 1 week, patients were 
randomized to either venlafaxine (mean daily dose 371 mg, 
range 300–375 mg/d) or imipramine (mean dose 206 mg, range 
50–450 mg/d, blood level 200–300 ng/mL) treatment. For details 
of dose adjustment, see Vermeiden et al. (2013). After 7 weeks, 
patients who achieved response (≥50% reduction in HAM-D 
scores) were kept on the same dose of the antidepressant with-
out concomitant medication (except for 6 of 40 patients who 
received lorazepam <3 mg/d). Most nonresponders received lith-
ium as addition to the ongoing antidepressant treatment.
Blood Sampling and Analysis
Blood samples were taken after the wash-out period, before 
treatment started (baseline), +7wks, and +6mos. Sampling took 
place at 8:00 am in the morning. Serum was stored at –80°C 
until collection of all samples was completed and shipped on 
dry ice to the Münster laboratory for measuring S100B levels. 
All samples were analyzed in the Elecsys S100 electrochemi-
luminescence assay in singles (Roche Diagnostics, Mannheim, 
Germany). The intra- and inter-assay coefficients of variation 
were 1.0 to 1.8% and 2.5 to 3.1%, respectively.
Statistical Analysis
Histograms were assessed to check continuous variables for 
normal distribution. Age deviated strongly from normal distri-
bution. Since it was only used as a predictor variable or covari-
ate in the main analyses that did not require the assumption 
of normal distribution, no transformation was applied for age 
data, and nonparametric Spearman’s correlation was calcu-
lated for this variable in the pretest. Otherwise, Pearson’s cor-
relations were calculated to assess the association between 2 
continuous variables. Then t tests for independent data were 
calculated to compare 2 independent samples. To compare 
S100B levels at the 3 time points, repeated-measures ANOVAs 
were calculated. The main hypothesis of this study was that 
baseline S100B levels alone and together with relevant clinical 
parameters predict treatment response. The dependent varia-
bles, acute (+7wks) and long-term (+6mos) treatment responses, 
were defined as percentage decrease in HAM-D scores after 
treatment in relation to baseline scores. For the differentia-
tion between responders and nonresponders, responders were 
defined as patients that reached a reduction of at least 50% in 
their HAM-D scores at +7wks. S100B serum levels at baseline 
(high, low), age, sex, HAM-D scores at baseline, recurrence of 
the disorder (no, yes), medication (venlafaxine, imipramine), 
and body mass index (BMI) were chosen as candidates for pre-
dictor variables of the linear regression model. Sample sizes 
of subgroups for gender, medication, response, and recurrence 
are depicted in supplementary Figure 1. Correlations were cal-
culated between treatment response and these variables. Since 
BMI, sex, and the initial HAM-D scores did not correlate to 
treatment response, the final model comprised baseline S100B 
levels, type of medication, age, and recurrence. To approach 
this question from another point of view, a repeated-measures 
ANCOVA was calculated with Hamilton scores at baseline, 
+7wks, and +6mos as within-subject variables and S100B levels 
at baseline (high/low) as between-subjects variable including 
the other predictor variables as covariates. Effects were con-
sidered significant if P < .05. All analyses were calculated using 
SPSS software (IBM, version 22).
Results
S100B Levels, Antidepressants, Age, and Recurrence: 
Relation with Treatment Response
Patients were between 33 and 67  years of age (52.1 ± 9.2, 
mean ± SD), had a body weight of 41 to 98 kg (71.0 ± 13.0), a BMI 
between 15.4 and 33.3 (23.8 ± 4.2), and a baseline HAM-D score 
of 18 to 30 (24.3 ± 3.2) indicating moderate to severe depression. 
After 7 weeks of treatment, either with venlafaxine or imipra-
mine HAM-D scores declined by 36.6 ± 32.2% (range: -26.3 to 
94.7%). At the 6-month follow-up, HAM-D scores were reduced 
by 37.8 ± 34.7% (range: -28.6 to 96.2%) compared with baseline.
First we analyzed the potential predictor variables for 
treatment response. Treatment response at both time points 
showed a moderate correlation with initial S100B serum lev-
els at baseline (Pearson’s correlation: +7wks: r  = .307, P  = .054; 
+6mos:  r = .334, P  = .035) (Figure 1a). To define groups with high 
and low baseline levels of S100B, this variable was dichotomized 
by a median split. Patients with high (≥.051 ng/mL) baseline 
S100B levels had a significantly larger improvement in HAM-D 
scores of about 50% compared with those with initially low 
levels (<.051 ng/mL) showing reductions of about only 20% (t 
test: +7wks: t(38)  =  -3.350, P  = .002; +6mos: t(38)  =  -3.172, P  = .003) 
(Figure 1b).
There was no significant difference in treatment response 
between venlafaxine- or imipramine-treated patients at +7wks, 
while venlafaxine-treated patients showed a significantly better 
response at +6mos (t test: +7wks: t(38) = -1.314, P = .197; +6mos: 
t(38) = -2.063, P = .046) (Figure  1c). Patients with recurrent epi-
sodes had a slightly reduced but statistically not significant 
acute treatment response at +7wks compared with patients with 
a first episode of depression (t test: t(38)  =  -1.685, P = .100) while 
recurrence had even less influence at +6mos (t test: t(38) = -1.357, 
P = .183) (Figure 1d). Age showed a moderate positive correlation 
with treatment response at both time points, however, without 
reaching statistical significance (Spearman’s rank correlation: 
+7wks: rs = .234, P = .146; +6mos: rs = .310, P = .051) (Figure  1e). In 
contrast, there was no association between treatment response 
and initial HAM-D scores, gender, or BMI (supplementary 
Figure  2a-c). Variables that showed at least a tendency for an 
association with treatment response at one time point (P ≤ .1) 
were included in linear regression models to predict acute and 
long-term treatment responses.
S100B Serum Levels Predict Treatment Response
Baseline S100B levels, medication, recurrence, and age 
accounted for 40.5% of the variation in the acute treatment 
response (adj. R2 = .405, P <  .001) and for 48.5% of the long-term 
treatment response (adj. R2 = .485, P <  .001) (Table  1a). Baseline 
S100B levels and medication turned out to be significant predic-
tors for both the acute (+7wks) and long-term (+6mos) treatment 
response, while age was also a significant predictor for the long-
term treatment response (Table 1a).
Since S100B levels have been the strongest and most signifi-
cant predictor for the treatment response at both time points, 
we calculated simple linear regression models with S100B levels 
at baseline (high/low) as the only predictor. While these models 
were significant for both time points, the predictive values with 
adjusted R2 = .208 (+7wks, P = .002) and adjusted R2 = .188 (+6mos, 
P = .003) were rather modest (Table 1b). The analysis of the sta-
tistical quality of serum S100B as treatment predictor (Table 2) 
revealed a sensitivity of about 79%, specificity of 65%, positive 
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Figure 1. (a) There was a significant association of moderate effect size between baseline S100 calcium binding protein B (S100B) levels and treatment response 
at both time points after treatment. Patients with higher baseline S100B levels improved more than those with initially lower S100B levels. (b) Patients with high 
baseline S100B levels (≥.051 ng/mL) showed a significantly larger relative reduction in Hamilton Depression Rating Scale (HAM-D) scores at both time points after 
treatment. (c) There was no significant difference in HAM-D reductions between venlafaxine- and imipramine-treated patients. (d) Patients with first episode 
depression showed a significant larger relative reduction in HAM-D scores than patients with recurrent depression after the 7-week treatment period (+7wks). (e) 
There was a moderate association between age and treatment response, with older patients improving a little better than younger ones at the 6-month follow-up 
investigation (+6mos).
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predictive value of 55%, and number of false positives of 22.5%. 
However, the negative predictive value was 85%, while the false 
negatives were only 7.5%, indicating that patients with low 
S100B levels can be classified with high precision as treatment 
nonresponders.
HAM-D scores at baseline did not differ between patients 
with high and low baseline S100B levels. However, patients with 
high baseline S100B levels showed larger reductions in HAM-D 
scores after 7 weeks and 6 months than those with initially low 
levels (repeated-measures ANCOVA on HAM-D scores controlled 
for medication, age, and recurrence: time x S100B high/low: 
F1.4,49.0 = 19.203, P < .001) (Table 3A).
S100B Serum Levels Are Stable over the Course of 
Treatment
To control whether elevated S100B levels are associated with 
more severe depression and therefore are more likely to be 
associated with an increased treatment response, we calculated 
the correlation between baseline S100B levels and severity of 
depression at baseline as assessed by HAM-D scores. There was 
no significant correlation between these variables (Pearson cor-
relation: r = .013, P = .938), indicating that elevated S100B levels 
are independent from depression severity. In addition, S100B 
levels did not change with clinical improvement over time, as 
indicated by the lack of a significant difference between S100B 
levels at the 3 time points (Table 3B) before treatment (baseline), 
+7wks, and +6mos, either as main effect of time (F1.4,25.8 = .532, 
P = .535) or as interaction effect between time and treatment 
response (F1.4,25.8 = .128, P = .812). However, as could be expected 
by the predictive property of S100B levels, responders had sig-
nificantly higher S100B levels than nonresponders (F1,18 = 5.635, 
P = .029). Since the number of samples for the final time point 
+6mos was quite small, this repeated-measures ANOVA was 
also calculated for the first 2 time points only, revealing simi-
lar results (time: F1,37 = .046, P = .832; time x response: F1,37 = .810, 
P = .374; response: F1,37 = 8.998, P = .005).
Discussion
This study examined whether circulating S100B levels in the 
serum of patients with melancholic depression are associated 
with outcome after antidepressant treatment. As hypothesized, 
patients with higher baseline levels of S100B showed signifi-
cantly larger reductions in HAM-D scores after treatment com-
pared with those with lower S100B baseline levels. Patients with 
low S100B levels could be classified as nonresponders with high 
precision. The severity of depression was not associated with 
S100B levels. Moreover, S100B levels did not differ between base-
line, +7wks, and +6mos time points.
S100B has been shown to exert neurotrophic and neuropro-
tective effects, especially on serotonergic neurons (Alexanian 
and Bamburg, 1999; Huttunen et al., 2000; Eriksen and Druse, 
2001), when it was available at nanomolar concentrations in 
contrast to neurotoxic effects at micromolar concentrations 
(Fano et al., 1995). On the basis of S100B levels in the lumbar 
cerebrospinal fluid of depressive patients, ventricular CSF levels 
have been estimated, strongly indicating that, in mood disor-
ders extracellular S100B levels in the brain are in the nanomo-
lar range far below micromolar concentrations (Schroeter et al., 
2013). Since there is strong evidence for reduced neurotrophic 
factor expression, impaired neuroplastic function, and even 
mild forms of brain atrophy in certain brain structures in major 
depression, it is assumed that restoring neuroplastic func-
tion in depressive patients is a fundamental part of behavioral 
improvement (Castrén, 2013). For instance, it has been shown 
that the antidepressant action of fluoxetine requires the induc-
tion of adult neurogenesis (Santarelli et al., 2003). Here it is of 
interest to note that intracerebroventricular and even intraperi-
toneal application of S100B increases progenitor cell prolifera-
tion as well as neuronal differentiation and survival of newborn 
cells in mice after brain injury (Kleindienst et al., 2005, 2013). 
So, elevated levels of S100B as found in one-half of the patients 
could indicate an increased neurotrophic potential and thereby 
contribute to therapy response by increasing brain plasticity. 
Table 2. Calculation of sensitivity, specificity, positive/negative pre-
dictive values, and rate of false positives/negatives for S100B levels 
as marker of therapy response using the median concentration at 
baseline as cut-off value.
Responders Nonresponders Total
Baseline S100B ≥.051 (ng/mL) 11 9 20
<.051 (ng/mL) 3 17 20
Total 14 26 40
Table 1. (a) Multiple linear regression models of acute and long-term treatment response with predictor variables S100B levels at baseline 
(ahigh/low), medication (bvenlafaxine/imipramine), age, and recurrence. (b) Simple linear regression model to predict acute and long-term 
treatment response from S100B serum levels at baseline as sole predictor. Bold figures indicate significant p-values and adjusted R2 values.
a) Multiple Linear 
Regression Models.
Acute Treatment Response +7wks Long-Term Treatment Response +6mos
B SE P B SE P
Baseline S100Ba 38.488 8.257 <.001*** 42.868 8.281 <.001***
Medicationb 21.839 8.293 .013* 31.537 8.318 <.001***
Age .800 .434 .074 1.037 .435 .023*
Recurrence (yes/no) 15.109 8.273 .076 11.904 8.298 .160
Adjusted R2 .405 .485
F (df) 7.645 (4,35) <.001*** 10.194 (4,35) <.001***
b) Simple Linear 
Regression 
Models.
Acute Treatment Response +7wks Long-Term Treatment Response +6mos
B SE P B SE P
Baseline S100Ba 30.335 9.055 .002* 31.333 9.879 .003**
Adjusted R2 .208 .188
F (df) 11.225 (1,38) .002** 10.059 (1,38) .003**
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Indeed, it has recently been shown that the action of the selec-
tive serotonin reuptake inhibitor fluoxetine involves the release 
of S100B from terminals of serotonergic neurons at the locus 
coeruleus where it increases the expression of the serotonin 
transporter at the site of norepinephrine synthesis (Baudry et 
al., 2010). Both drugs, the serotonine-norepinephrine reuptake 
inhibitor venlafaxine and the tricyclic antidepressant imipra-
mine, work as inhibitors of both serotonin and norepinephrine 
reuptake (Holliday and Benfield, 1995; Humble, 2000) and thus 
might directly modulate these processes. These findings might 
suggest that patients with higher S100B expression have an 
increased availability of this neurotrophic factor, which may 
promote the antidepressant action at the intersection of sero-
tonergic and noradrenergic neurotransmission. It would be of 
interest to know whether elevated S100B levels are especially 
beneficial for the successful action of certain antidepressants 
such as those with a strong effect on the inhibition of serotonin 
reuptake, while patients with low S100B levels might better ben-
efit from different antidepressants or other treatments.
The main finding of the present study that baseline S100B 
levels are associated with antidepressant response is in accord-
ance with 2 previous reports (Arolt et al., 2003; Jang et al., 2008). 
In addition, in the present study S100B levels were not associ-
ated with severity of depression. Instead, our findings sug-
gest that S100B predicts treatment response independent of 
depression severity. In our study, S100B levels did not change 
over the course of treatment. While there are some inconsistent 
reports whether S100B levels decline with treatment response 
(Schroeter et al., 2002) or not (Hetzel et al., 2005; Jang et al., 2008; 
Schroeter et al., 2008), the present study strongly suggests that 
S100B rather is a trait marker for antidepressant responsiveness 
than a state marker for depression severity. In addition, there 
exist rather inconclusive findings whether S100B levels in serum 
or cerebrospinal fluid of depressive patients are elevated com-
pared with healthy controls (Grabe et al., 2001; Schroeter et al., 
2002, 2008; Hetzel et al., 2005) or not (Jang et al., 2008; Schmidt 
et al., 2015). These contradictory findings indicate that the role 
of S100B in major depression is rather complex and still far 
from being understood. In a recent study, S100B overexpressing 
mice displayed an increased reactivity to environmental stim-
uli as shown by an increased behavioral and neural plasticity 
(Buschert et al., 2013). Thus, elevated S100B expression might be 
associated with a differential susceptibility to environmental 
stimuli and could act as a plasticity factor in the way it has been 
proposed by Belsky and Pluess (2009). Consequently, functional 
variants in the S100B gene would represent plasticity alleles 
rather than risk alleles (Belsky et al., 2009).
Since S100B is not only expressed in the brain but also in a 
number of peripheral tissues such as white fat, skeletal muscle, 
or heart (Zimmer et al, 1995), serum levels need not necessarily 
reflect individual variation in S100B expression in the brain. They 
could also be influenced by altered extra cranial S100B expression, 
for example, in patients with comorbid heart disease, obesity, or 
metabolic syndrome (Mazzini et al., 2005, 2007, 2009; Steiner et 
al., 2010a, 2010b), which might be a possible explanation for the 
sometimes contradictory findings on the role of S100B in major 
depression that are found in the literature. One study showed an 
association of S100B levels with BMI that was mainly due to sub-
jects with a BMI > 30 who showed markedly higher S100B levels 
compared with patients with a smaller BMI (Steiner et al., 2010a). 
In our study, BMI, in contrast to S100B levels, showed no associa-
tion with treatment response, suggesting that the effects of S100B 
were not due to variations in BMI.
It should be noted that altered levels of S100B have been 
found in other neuropsychiatric disorders such as schizophrenia, 
autism, and Alzheimer’s disease (Peskind et al., 2001; Al-Ayadhi 
and Mostafa, 2012; Aleksovska et  al., 2014), implicating that 
alterations in levels of this molecule are not specific for major 
depression. Altered S100B might have different causes and con-
sequences in these disorders, and it is not clear whether its main 
function is always the contribution to neuroplasticity. This may 
be true when S100B levels are in a physiological range, as is the 
case in MDD patients, or during early stages of neurodegenera-
tive diseases. However, there is also evidence that S100B might 
be a glial marker for neuroinflammation or even contribute to 
inflammation and neurodegeneration in pathological conditions 
(Rothermundt et al., 2003; Donato et al., 2009; Mori et al., 2010).
Despite the precise prediction of treatment nonresponse by low 
S100B levels, high serum S100B is not sufficient as sole predictor of 
antidepressant treatment. This is the same with a number of other 
candidate biomarkers for antidepressant treatment responses 
like T-lymphocytic CREB, inflammatory markers, functional or 
Table 3. (a) Hamilton scores at baseline and after 7 weeks and 6 months for all patients and separated for those with high and low baseline 
S100B levels. (b) S100B levels at the 3 different time points: baseline, +7wks, and +6mos in all patients as well as separated by response.
a) Hamilton Scores.
All patients Baseline S100B high Baseline S100B low
N M 95 % CI N M 95 % CI N M 95 % CI
Baseline 40 24.28 [23.3,25.3] 20 24.85 [23.1,26.6] 20 23.70 [22.5,24.9]
+7wks 40 15.43 [12.9,17.9] 20 12.40 [8.4,16.4] 20 18.45 [15.7,21.2]
+6mos 40 15.10 [12.4,17.8] 20 11.90 [7.6,16.2] 20 18.30 [15.2,21.4]
b) S100B Levels.
All patients Responders Nonresponders
N M (ng/mL) 95 % CI N M (ng/mL) 95 % CI N M (ng/mL) 95 % CI
Baseline 40 .050 [.043,.057] 14 .061 [.047,.074] 26 .044 [.036,.052]
+7wks 39 .049 [.042,.057] 14 .063 [.049,.078] 25 .041 [.034,.049]
+6mos 20 .055 [.043,.067] 12 .064 [.045,.082] 8 .042 [.033,.051]
Please note that at +6mos, fewer blood samples were available, especially from nonresponders, probably accounting for a slightly elevated mean level in the total 
group at this time point.
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structural neuroimaging, or gene-environment interactions in 
the etiology of the disorder (Fu et  al., 2013; Klengel and Binder, 
2013; Lim et al., 2013; Raison et al., 2013; Sämann et al., 2013; Uher 
et al., 2014). Since S100B also has an immune-modulatory func-
tion (Donato et  al., 2009) and immune dysregulation has been 
frequently described in major depression (eg, Miller et  al., 2009; 
Zunszain et al., 2013; Carvalho et al., 2014; Grosse et al., 2015), it 
would be interesting to analyze how S100B relates to markers of the 
immune system. Our group has previously shown that increased 
percentages of CD8+ cytotoxic T cells and decreased percentages 
of natural killer cells are associated with a poor response to anti-
depressant treatment in the same cohort of patients with melan-
cholic depression (Grosse et  al., 2015). In addition, we described 
increased proinflammatory gene expression in these patients 
(Carvalho et al., 2014). Therefore, it could be a valuable approach 
to integrate all these parameters into a combined biosignature, 
analyze its predictive value for antidepressant treatment response, 
and test it in an independent cohort of patients. To reach the goal 
of sufficient prediction of treatment response, such an approach of 
combining multiple biomarkers and defining algorithms for multi-
variate analysis would probably be necessary (Kennedy et al., 2012).
Limitations
There are several limitations to the present study. First, in this 
randomly controlled treatment trial, only severely depressed 
patients with melancholic features were included. Thus, it is not 
possible to draw conclusions on patients with other forms of 
depression or depression of different subtypes such as atypical, 
psychotic, anxious, or unspecified depression. Second, although 
the sample size of the present study was sufficient to analyze 
the predictive value of S100B levels for the treatment response, it 
was too small to allow for the comparison of the antidepressant 
treatment subgroups. Based on the finding that S100B acts as a 
mediator between serotonergic terminals and serotonin trans-
porter expression in the noradrenergic locus coeruleus (Baudry et 
al., 2010), it can be hypothesized that patients with higher S100B 
levels might profit more from certain types of antidepressants 
that act preferentially on the serotonergic system from those 
that have different modes of action. Therefore, the choice of only 
two antidepressants is another limitation that does not allow the 
generalization of the findings to other antidepressants. Finally, it 
should be mentioned that serum S100B levels are only an indica-
tor of S100B concentrations in the brain. It has been estimated 
that S100B is able to pass the blood brain barrier to a certain 
extent (Reiber et al., 2001), but it has to be kept in mind that extra-
cranial sources of S100B might interfere with this interpretation. 
While our rather homogenous study population did not seem to 
be affected by this interference in a considerable extent, this situ-
ation can be different in more heterogeneous patient groups.
Conclusion
Despite the aforementioned limitations, this study provides 
considerable evidence for serum S100B levels as a predictive 
biomarker of antidepressant treatment response in patients 
with melancholic depression. Especially nonresponders can be 
detected by low S100B levels with high precision. Since S100B 
serum levels did not change with successful treatment and were 
not associated with severity of depressive symptoms, S100B 
might be utilized as a trait marker for neural plasticity rather 
than as a state marker for acute depressive episodes. To general-
ize these findings, future studies on S100B levels as a predictor of 
antidepressant response should include other antidepressants 
and patients with other subtypes of major depression as well. 
These studies will show which treatments might be more effec-
tive in patients with low S100B levels. Then, the clinician will 
be able to choose the right treatment based on this biomarker, 
reducing patients’ burden of nonresponding.
Supplementary Material
For supplementary material accompanying this paper, visit 
http://www.ijnp.oxfordjournals.org/
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